Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 47.7% in July

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 15,800 shares, an increase of 47.7% from the June 30th total of 10,700 shares. Based on an average trading volume of 58,000 shares, the short-interest ratio is currently 0.3 days.

Global X Genomics & Biotechnology ETF Price Performance

Global X Genomics & Biotechnology ETF stock traded down $0.09 during mid-day trading on Monday, reaching $11.63. 41,555 shares of the company were exchanged, compared to its average volume of 63,355. The company has a fifty day simple moving average of $10.71 and a 200-day simple moving average of $10.90. Global X Genomics & Biotechnology ETF has a 12 month low of $8.63 and a 12 month high of $12.53. The firm has a market cap of $86.53 million, a PE ratio of -4.97 and a beta of 1.03.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Hedge funds have recently added to or reduced their stakes in the stock. Corrado Advisors LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at $638,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 16.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 377,749 shares of the company’s stock valued at $4,431,000 after purchasing an additional 53,178 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 4th quarter valued at $544,000. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Global X Genomics & Biotechnology ETF by 9.0% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 250,986 shares of the company’s stock valued at $2,901,000 after purchasing an additional 20,812 shares in the last quarter. Finally, James J. Burns & Company LLC acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter valued at $181,000. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.